Climate change has the potential to impact everyone’s health and wellbeing, and exacerbates many of the diseases we work to treat.

We have set ambitious sustainability goals to reduce our global environmental footprint 50% by 2029, and achieve true zero emissions by 2050.

In support of these goals, we are committed to:

We’ve set additional 2025 targets for our headquarters in South San Francisco:

We have long prioritized sustainability across all facets of our business, and were one of the first biotech companies to publish our greenhouse gas emissions and water use reduction goals in 2006. Since then, some of our cutting-edge programs and practices include:

• Launching the first double-decker electric commuter bus program in the U.S., along with partnerships that support underserved communities and expansive sustainable commute options for our workforce
• Housing one of the largest corporate solar installations on the San Francisco Bay Area peninsula, contributing to our 2025 goal to transition 100% of our electricity to sustainable energy¹
• Championing healthy building design and construction at our headquarters, with one net-zero building, one LEED Platinum building, and multiple LEED Gold, WELL and Fitwel certified buildings
• Partnering with local community colleges for chemical reuse programs
• Participating in the U.S. Department of Energy's Better Climate Challenge across all of our U.S. manufacturing sites

California SB 261 Climate-Related Financial Risk Report – Genentech is a member of the Roche Group, and its operations are encompassed in the Roche Group’s latest Sustainability Report included in the Roche Group’s Annual Report. For Genentech’s SB 261 disclosure, please see Chapter 6 of the Roche Group’s Sustainability Report “Task Force on Climate-related Financial Disclosures (TCFD)” at pages 117- 126 of the Annual Report 2024.